Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Blood (2024) 144 (21): 2237–2247.

https://doi.org/10.1182/blood.2024024493

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of HOX Genes: Trial in Progress

Ghayas C. Issa, Kuo-Kai Chin, James S. Blachly, Aziz Farhat, Lianchun Xiao, Jing Ning, Branko Cuglievan, Neerav Shukla, Koji Sasaki, Sanam Loghavi, Sheng Cai, Hagop M. Kantarjian, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 5995.

https://doi.org/10.1182/blood-2024-203466

Published: 2024

Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Blood (2024) 144 (Supplement 1): 211.

https://doi.org/10.1182/blood-2024-194384

Published: 2024

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Blood (2022) 140 (Supplement 1): 150–152.

https://doi.org/10.1182/blood-2022-164849

Published: 2022

Journal Articles

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Blood (2019) 134 (26): 2361–2368.

https://doi.org/10.1182/blood.2019001641

Published: 2019

Includes: Supplemental data

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Kavitha Ramaswamy, MD, Christopher Forlenza, MD, Rachel Kobos, MD, Peter G. Steinherz, MD, Neerav Shukla, MD

Blood (2018) 132 (Supplement 1): 79.

https://doi.org/10.1182/blood-2018-99-115185

Published: 2018

Journal Articles

High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL

Blood (2017) 130 (Supplement 1): 1326.

https://doi.org/10.1182/blood.V130.Suppl_1.1326.1326

Published: 2017

Journal Articles

Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma

Nitya Gulati, MBBS, Farid Boulad, MD, Maria I. Cancio, MD, Kevin J. Curran, MD, Carolyn Jackson, Nancy Kernan, MD, Andrew L. Kung, MD PhD, Richard O'Reilly, MD, Susan Prockop, MD, Kavitha Ramaswamy, MD, Andromachi Scaradavou, MD, Barbara Spitzer, Neerav Shukla, MD, Peter G. Steinherz, MD, Christopher Forlenza

Blood (2017) 130 (Supplement 1): 5172.

https://doi.org/10.1182/blood.V130.Suppl_1.5172.5172

Published: 2017

Journal Articles

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

Neerav Shukla, MD, Cynthia Wetmore, MD PhD, Maureen M O'Brien, MD, Lewis B. Silverman, MD, Patrick Brown, MD, Todd M Cooper, DO, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Ben Suttle, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2016) 128 (22): 2780.

https://doi.org/10.1182/blood.V128.22.2780.2780

Published: 2016

Journal Articles

Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation

Lisa Giulino Roth, MD, Tara O'Donohue MD, Tanya Trippett, MD, Elizabeth Klein, MPH, Nancy A. Kernan, MD, Rachel Kobos, MD, Susan Prockop, MD, Andromachi Scaradavou, MD, Neerav Shukla, MD, Peter G Steinherz, MD, Alison J Moskowitz, MD, Craig H. Moskowitz, MD, Farid Boulad, MD

Blood (2015) 126 (23): 2000.

https://doi.org/10.1182/blood.V126.23.2000.2000

Published: 2015

Journal Articles

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

Blood (2015) 126 (23): 2533.

https://doi.org/10.1182/blood.V126.23.2533.2533

Published: 2015

Journal Articles

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Neerav Shukla, MD, Maureen M. O'Brien, MD, Lewis B. Silverman, MD, Melinda Pauly, MD, Cynthia Wetmore, MD PhD, Mignon L. Loh, MD, James A. Whitlock, MD, Patrick Brown, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Patricia Pimentel, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2015) 126 (23): 3792.

https://doi.org/10.1182/blood.V126.23.3792.3792

Published: 2015

Journal Articles

Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL

Kevin J. Curran, MD, Isabelle Riviere, PhD, Rachel Kobos, MD, Nancy A. Kernan, MD, Farid Boulad, MD, Susan E. Prockop, MD, Andromachi Scaradavou, MD, Thomas M. Renaud, MD, Neerav Shukla, MD, Peter G Steinherz, MD, Jae H Park, MD, Craig S. Sauter, MD, Richard J O'Reilly, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 3716.

https://doi.org/10.1182/blood.V124.21.3716.3716

Published: 2014

Journal Articles

Utility of Combined DNA and RNA Next Generation Sequencing in Leukemias for Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice

Catherine C. Coombs, MD, Aaron D. Viny, MD MS, Jie He, PhD, Rachel Kobos, MD, Doron Lipson, PhD, Neerav Shukla, MD, Kristina M. Knapp, BS, Geoff Otto, PhD, Omar Abdel-Wahab, MD, Eytan M. Stein, Raajit K. Rampal, MD PhD, Vincent A. Miller, MD, Ahmet Dogan, MD PhD, Marcel R.M. van den Brink, MD PhD, Scott A. Armstrong, MD PhD, Phil J Stephens, PhD, Martin S. Tallman, MD, Ross L. Levine, MD

Blood (2014) 124 (21): 1039.

https://doi.org/10.1182/blood.V124.21.1039.1039

Published: 2014

Journal Articles

Myeloablative Double-Unit Cord Blood Transplantation (CBT) in Pediatric Patients with High-Risk Acute Leukemia Demonstrates Encouraging Disease-Free Survival with Both TBI and Chemotherapy-Only-Based Conditioning

Andromachi Scaradavou, MD, Marissa N Lubin, BA, Patrick Hilden, MS, Farid Boulad, MD, Kevin J. Curran, MD, Rachel Kobos, MD, Susan E. Prockop, MD, Richard J. O'Reilly, MD, Jo-Ann Tonon, Courtney Byam, BS, Peter G Steinherz, MD, Neerav Shukla, MD, Aisha Hasan, MD, Thomas M. Renaud, MD, Nicole Zakak, N.P., Nancy A. Kernan, MD, Juliet N. Barker, MBBS(Hons), FRACP

Blood (2014) 124 (21): 2578.

https://doi.org/10.1182/blood.V124.21.2578.2578

Published: 2014

Journal Articles

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

Karuna Ganesh, MBBChir, PhD, Connie Batlevi, MD PhD, Zhigang Zhang, PhD, Hani Hassoun, MD, Nikoletta Lendvai, MD PhD, Heather Landau, MD, Craig H. Moskowitz, MD, Philip Caron, MD PhD, Robert Motzer, MD, Sergio A Giralt, MD, Paul Hamlin, MD, Stuart M. Lichtman, MD, Matthew J. Matasar, MD MS, Carol S Portlock, MD, Neerav Shukla, MD, Carol Wasserheit-Lieblich, MD, Andrew D. Zelenetz, MD PhD, John F. Gerecitano, MD PhD

Blood (2014) 124 (21): 3487.

https://doi.org/10.1182/blood.V124.21.3487.3487

Published: 2014

Journal Articles

Phase II Trial of Clofarabine in Combination with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Pediatric Patients with Refractory or Relapsed Acute Leukemia

Neerav Shukla, MD, Rachel Kobos, MD, Thomas M. Renaud, MD, Laurel Steinherz, M.D., Peter G Steinherz, MD

Blood (2012) 120 (21): 1514.

https://doi.org/10.1182/blood.V120.21.1514.1514

Published: 2012

NARROW

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of HOX Genes: Trial in Progress

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL

Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL

Utility of Combined DNA and RNA Next Generation Sequencing in Leukemias for Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice

Myeloablative Double-Unit Cord Blood Transplantation (CBT) in Pediatric Patients with High-Risk Acute Leukemia Demonstrates Encouraging Disease-Free Survival with Both TBI and Chemotherapy-Only-Based Conditioning

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

Phase II Trial of Clofarabine in Combination with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Pediatric Patients with Refractory or Relapsed Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only